FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076164772> ?p ?o ?g. }

• W2076164772 endingPage "425.e4" @default.
• W2076164772 startingPage "416" @default.
• W2076164772 abstract "Background & AimsIndoleamine 2,3 dioxygenase-1 (IDO1) catabolizes tryptophan along the kynurenine pathway. Although IDO1 is expressed in inflamed and neoplastic epithelial cells of the colon, its role in colon tumorigenesis is not well understood. We used genetic and pharmacologic approaches to manipulate IDO1 activity in mice with colitis-associated cancer and human colon cancer cell lines.MethodsC57Bl6 wild-type (control), IDO1-/-, Rag1-/-, and Rag1/IDO1 double-knockout mice were exposed to azoxymethane and dextran sodium sulfate to induce colitis and tumorigenesis. Colitis severity was assessed by measurements of disease activity, cytokine levels, and histologic analysis. In vitro experiments were conducted using HCT 116 and HT-29 human colon cancer cells. 1-methyl tryptophan and small interfering RNA were used to inhibit IDO1. Kynurenine pathway metabolites were used to simulate IDO1 activity.ResultsC57Bl6 mice given pharmacologic inhibitors of IDO1 and IDO1-/- mice had lower tumor burdens and reduced proliferation in the neoplastic epithelium after administration of dextran sodium sulfate and azoxymethane than control mice. These reductions also were observed in Rag1/IDO1 double-knockout mice compared with Rag1-/- mice (which lack mature adaptive immunity). In human colon cancer cells, blockade of IDO1 activity reduced nuclear and activated β-catenin, transcription of its target genes (cyclin D1 and Axin2), and, ultimately, proliferation. Exogenous administration of IDO1 pathway metabolites kynurenine and quinolinic acid led to activation of β-catenin and proliferation of human colon cancer cells, and increased tumor growth in mice.ConclusionsIDO1, which catabolizes tryptophan, promotes colitis-associated tumorigenesis in mice, independent of its ability to limit T-cell–mediated immune surveillance. The epithelial cell–autonomous survival advantage provided by IDO1 to colon epithelial cells indicate its potential as a therapeutic target. Indoleamine 2,3 dioxygenase-1 (IDO1) catabolizes tryptophan along the kynurenine pathway. Although IDO1 is expressed in inflamed and neoplastic epithelial cells of the colon, its role in colon tumorigenesis is not well understood. We used genetic and pharmacologic approaches to manipulate IDO1 activity in mice with colitis-associated cancer and human colon cancer cell lines. C57Bl6 wild-type (control), IDO1-/-, Rag1-/-, and Rag1/IDO1 double-knockout mice were exposed to azoxymethane and dextran sodium sulfate to induce colitis and tumorigenesis. Colitis severity was assessed by measurements of disease activity, cytokine levels, and histologic analysis. In vitro experiments were conducted using HCT 116 and HT-29 human colon cancer cells. 1-methyl tryptophan and small interfering RNA were used to inhibit IDO1. Kynurenine pathway metabolites were used to simulate IDO1 activity. C57Bl6 mice given pharmacologic inhibitors of IDO1 and IDO1-/- mice had lower tumor burdens and reduced proliferation in the neoplastic epithelium after administration of dextran sodium sulfate and azoxymethane than control mice. These reductions also were observed in Rag1/IDO1 double-knockout mice compared with Rag1-/- mice (which lack mature adaptive immunity). In human colon cancer cells, blockade of IDO1 activity reduced nuclear and activated β-catenin, transcription of its target genes (cyclin D1 and Axin2), and, ultimately, proliferation. Exogenous administration of IDO1 pathway metabolites kynurenine and quinolinic acid led to activation of β-catenin and proliferation of human colon cancer cells, and increased tumor growth in mice. IDO1, which catabolizes tryptophan, promotes colitis-associated tumorigenesis in mice, independent of its ability to limit T-cell–mediated immune surveillance. The epithelial cell–autonomous survival advantage provided by IDO1 to colon epithelial cells indicate its potential as a therapeutic target." @default.
• W2076164772 created "2016-06-24" @default.
• W2076164772 creator A5001463578 @default.
• W2076164772 creator A5027749474 @default.
• W2076164772 creator A5030317845 @default.
• W2076164772 creator A5046720476 @default.
• W2076164772 creator A5049151282 @default.
• W2076164772 creator A5063539379 @default.
• W2076164772 creator A5064181559 @default.
• W2076164772 creator A5077968110 @default.
• W2076164772 creator A5090766228 @default.
• W2076164772 date "2013-08-01" @default.
• W2076164772 modified "2023-10-15" @default.
• W2076164772 title "IDO1 Metabolites Activate β-catenin Signaling to Promote Cancer Cell Proliferation and Colon Tumorigenesis in Mice" @default.
• W2076164772 cites W168107337 @default.
• W2076164772 cites W1966481035 @default.
• W2076164772 cites W1967026374 @default.
• W2076164772 cites W1967909946 @default.
• W2076164772 cites W1977831876 @default.
• W2076164772 cites W1980386074 @default.
• W2076164772 cites W1991075838 @default.
• W2076164772 cites W199523218 @default.
• W2076164772 cites W1996845948 @default.
• W2076164772 cites W1998142996 @default.
• W2076164772 cites W1999601075 @default.
• W2076164772 cites W2010378562 @default.
• W2076164772 cites W2015336843 @default.
• W2076164772 cites W2034445092 @default.
• W2076164772 cites W2038859574 @default.
• W2076164772 cites W2042173734 @default.
• W2076164772 cites W2060991688 @default.
• W2076164772 cites W2066433865 @default.
• W2076164772 cites W2073234210 @default.
• W2076164772 cites W2081861063 @default.
• W2076164772 cites W2085852125 @default.
• W2076164772 cites W2086946343 @default.
• W2076164772 cites W2092642151 @default.
• W2076164772 cites W2092950801 @default.
• W2076164772 cites W2101567516 @default.
• W2076164772 cites W2101804567 @default.
• W2076164772 cites W2102512718 @default.
• W2076164772 cites W2127903252 @default.
• W2076164772 cites W2131303799 @default.
• W2076164772 cites W2133244416 @default.
• W2076164772 cites W2141304385 @default.
• W2076164772 cites W2154417660 @default.
• W2076164772 cites W2166008430 @default.
• W2076164772 cites W2166063624 @default.
• W2076164772 cites W2166281548 @default.
• W2076164772 cites W2170631284 @default.
• W2076164772 cites W2171195586 @default.
• W2076164772 cites W2232026888 @default.
• W2076164772 cites W2403060022 @default.
• W2076164772 doi "https://doi.org/10.1053/j.gastro.2013.05.002" @default.
• W2076164772 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3722304" @default.
• W2076164772 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23669411" @default.
• W2076164772 hasPublicationYear "2013" @default.
• W2076164772 type Work @default.
• W2076164772 sameAs 2076164772 @default.
• W2076164772 citedByCount "129" @default.
• W2076164772 countsByYear W20761647722013 @default.
• W2076164772 countsByYear W20761647722014 @default.
• W2076164772 countsByYear W20761647722015 @default.
• W2076164772 countsByYear W20761647722016 @default.
• W2076164772 countsByYear W20761647722017 @default.
• W2076164772 countsByYear W20761647722018 @default.
• W2076164772 countsByYear W20761647722019 @default.
• W2076164772 countsByYear W20761647722020 @default.
• W2076164772 countsByYear W20761647722021 @default.
• W2076164772 countsByYear W20761647722022 @default.
• W2076164772 countsByYear W20761647722023 @default.
• W2076164772 crossrefType "journal-article" @default.
• W2076164772 hasAuthorship W2076164772A5001463578 @default.
• W2076164772 hasAuthorship W2076164772A5027749474 @default.
• W2076164772 hasAuthorship W2076164772A5030317845 @default.
• W2076164772 hasAuthorship W2076164772A5046720476 @default.
• W2076164772 hasAuthorship W2076164772A5049151282 @default.
• W2076164772 hasAuthorship W2076164772A5063539379 @default.
• W2076164772 hasAuthorship W2076164772A5064181559 @default.
• W2076164772 hasAuthorship W2076164772A5077968110 @default.
• W2076164772 hasAuthorship W2076164772A5090766228 @default.
• W2076164772 hasBestOaLocation W20761647721 @default.
• W2076164772 hasConcept C121608353 @default.
• W2076164772 hasConcept C170493617 @default.
• W2076164772 hasConcept C182704531 @default.
• W2076164772 hasConcept C185592680 @default.
• W2076164772 hasConcept C203014093 @default.
• W2076164772 hasConcept C2775862500 @default.
• W2076164772 hasConcept C2776706248 @default.
• W2076164772 hasConcept C2776710720 @default.
• W2076164772 hasConcept C2777503454 @default.
• W2076164772 hasConcept C2778452354 @default.
• W2076164772 hasConcept C2780669762 @default.
• W2076164772 hasConcept C3018440083 @default.
• W2076164772 hasConcept C502942594 @default.
• W2076164772 hasConcept C515207424 @default.
• W2076164772 hasConcept C526805850 @default.
• W2076164772 hasConcept C54355233 @default.

• next